Dupilumab improves respiratory symptoms in patients with moderate-to-severe COPD with type 2 inflammation in phase 3 BOREAS trial

<bold>BACKGROUND:</bold> IL-4 and IL-13 are key and central drivers of type 2 inflammation. Dupilumab, a fully human monoclonal antibody that blocks the shared receptor component for IL-4 and IL-13, improved health-related quality of life and COPD symptoms in the phase 3 BOREAS trial (<ext-link>NCT03930732</ext-link>). This analysis evaluates the effect of dupilumab on daily symptom burden using the Evaluating Respiratory Symptoms in COPD (E-RS™:COPD) tool by domain. <bold>METHODS:</bold> In BOREAS, patients with moderate-to-severe airflow limitation and type 2 inflammation (screening blood eosinophils ≥300 cells/µL), on triple therapy, received add-on dupilumab 300mg q2w or placebo for 52 weeks. E-RS domain scores (total, breathlessness, chest symptoms, cough and sputum) were evaluated in patients on a daily basis, to determine weekly average scores, from baseline up to Week 52. <bold>RESULTS:</bold> In the ITT population, E-RS:COPD total score change from baseline at Week 52 for dupilumab (n=468) vs placebo (n=471) was significantly greater (least squares [LS] mean difference –1.137; <italic>P</italic>=0.0012). Compared to placebo, dupilumab demonstrated nominally significant improvements in all 3 E-RS:COPD domains by Week 52 <bold>(Figure)</bold>. Dupilumab demonstrated an acceptable safety profile. <bold>CONCLUSIONS:</bold> Dupilumab improved daily symptom frequency and severity in all E-RS:COPD total and domains for patients with COPD and type 2 inflammation in BOREAS. <fig><object-id>erj;64/suppl_68/PA4786/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>